CGP 36742: The first orally active GABAB blocker improves the cognitive performance of mice, rats, and rhesus monkeys

doi:10.1016/0163-1047(93)90729-2

Behavioral and Neural Biology

Volume 60, Issue 1, July 1993, Pages 62-68

https://doi.org/10.1016/0163-1047(93)90729-2 Get rights and content

The learning capacity of experimental animals in cognitive tests can be improved by blockade of the GABA_B receptors. After treatment with the GABA_B antagonist CGP 36742, mice performed better in a passive-avoidance test; rats did likewise in a partner-recognition test, and rhesus monkeys also in a “conditional spatial color” task. The effects demonstrated in these three different species and covering diverse manifestations of learning and memory give reason to hope that this new active principle may prove therapeutically useful.

References (33)

AndréP. et al.
Increased acetylcholine and quisqualatate responsiveness following blockade of GABA_B receptors
European Journal of Pharmacology
(1992)
BeaumontK. et al.
Muscimol binding in rat brain: Associations with synaptic GABA receptors
Brain Research
(1978)
BoweryN.
GABA_B receptors and their significance in mammalian pharmacology
Trends in Pharmacological Science
(1989)
GaffanD. et al.
A comparison of the effects of fornix transsection and sulcus principalis ablation upon spatial learning in monkeys
Behavioural Brain Research
(1989)
GoldP.E. et al.
The mnemon and its juices: Neuromodulation of memory processes
Behavioral and Neural Biology
(1983)
OlpeH.R. et al.
CGP 35348: A centrally active blocker of GABA_B receptors
European Journal of Pharmacology
(1990)
BartusR.T. et al.
The cholinergic hypothesis: A historical overview, current perspective, and future directions
BittigerH. et al.
GABA_B antagonists: Potential new drugs
Pharmacology Communications
(1992)
BittigerH. et al.
Biochemistry, electrophysiology and pharmacology of a new GABA_B antagonist: CGP 35348
BoweryN.G. et al.
Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor
Nature
(1980)

CastellanoC. et al.

GABAergic modulation of memory

CastellanoC. et al.

Post-training systemic and intraamygdala administration of the GABA_B agonist Baclofen impairs retention

Behavioral and Neural Biology

(1979)

DaviesC.H. et al.

GABA_B autoreceptors regulate the induction of LTP

Nature

(1991)

DutarP. et al.

A physiological role for GABA_B receptors in the central nervous system

Nature

(1988)

GaffanD. et al.

Place memory and scene memory: Effects of fornix transsections in the monkey

Experimental Brain Research

(1989)

GehanE.

A generalized Wilcoxon test for comparing arbitrarily single censored samples

Biometrika

(1980)

Cited by (110)

How do stupendous cannabinoids modulate memory processing via affecting neurotransmitter systems?
2021, Neuroscience and Biobehavioral Reviews
In the present study, we wanted to review the role of cannabinoids in learning and memory in animal models, with respect to their interaction effects with six principal neurotransmitters involved in learning and memory including dopamine, glutamate, GABA (γ-aminobutyric acid), serotonin, acetylcholine, and noradrenaline. Cannabinoids induce a wide-range of unpredictable effects on cognitive functions, while their mechanisms are not fully understood. Cannabinoids in different brain regions and in interaction with different neurotransmitters, show diverse responses. Previous findings have shown that cannabinoids agonists and antagonists induce various unpredictable effects such as similar effect, paradoxical effect, or dualistic effect. It should not be forgotten that brain neurotransmitter systems can also play unpredictable roles in mediating cognitive functions. Thus, we aimed to review and discuss the effect of cannabinoids in interaction with neurotransmitters on learning and memory. In addition, we mentioned to the type of interactions between cannabinoids and neurotransmitter systems. We suggested that investigating the type of interactions is a critical neuropharmacological issue that should be considered in future studies.
Synopsis of recent synthetic methods and biological applications of phosphinic acid derivatives
2020, Tetrahedron
Citation Excerpt :
Other important attributes of these scaffolds would be drug applications for diverse therapeutic implementation. Many of them are currently in clinical research and development, summarizing the most important developments of drug design based on phosphinic acids (Fig. 5) [237–304]. The literature survey presented herein clearly demonstrate that phosphinic acid derivatives are readily obtainable and a valuable building block in organic synthesis.
The chemistry of phosphinic acid derivatives has attracted increasing attention in both synthetic organic and biological fields, and great progress in the application of such compounds has been achieved in recent years. This review aims to document a systematic account of the prevailing methods for the synthesis of acyclic/cyclic phosphinic acids either in enantiopure or in racemic form. The most important among them are Hirao cross-coupling reaction, Michael addition to olefins, Atherton–Todd reaction and Michaelis-Arbuzov reaction. Other noteworthy methods applied for this purpose are benzylation and allylation of hypophosphorous acid, hydrophosphinylation of aldehydes or alkenes and phosphorylation of strained P-heterocycles. Parallel synthetic methods leading to heterocyclic phosphinic acids such as phospholes, azaphospholidines, phosphorines, 1,2-oxaphosphorines, 1,3-azaphosphorines, 1,4,2-oxazaphosphinanes, phosphindoles, and benzazaphosphorines are also disclosed. Finally, selected significant applications in medicinal chemistry of the title compounds like Zn-metalloprotease Inhibitors, prodrug and drug applications are described briefly here. The bibliography includes 304 references.
Role of CA1 GABA<inf>A</inf> and GABA<inf>B</inf> receptors on learning deficit induced by D-AP5 in passive avoidance step-through task
2018, Brain Research
Citation Excerpt :
Given that baclofen can affect both acquisition and consolidation of memory in Morris water maze task, it would be expected that GABABR antagonists also produce some effect. Administration of GABABR antagonists to investigate memory acquisition in passive avoidance tasks induced a positive effect only in studies that an antagonist was administered repeatedly and systemically prior to the training (Yu et al., 1997), or specifically when the drug was administered orally (Mondadori et al., 1993). No effect was observed When the drug was not administered systemically (Zarrindast et al., 2008) or was administered only once (Dubrovina and Zinov'ev, 2008).
To investigate the interaction between hippocampal γ-aminobutyric acid GABA_A receptor (GABA_AR) or GABA_B receptor (GABA_BR) and N-methyl-D-aspartate receptor (NMDAR) in the acquisition of passive avoidance memory in rats, we used GABA_A or GABA_B agents, D-AP5 (as a NMDAR antagonist), and a combination of the mentioned drugs in a step-through task. All agents were microinjected into the intra-CA1 regions at a volume of 1 µl/rat, prior to training. GABA_AR agonist muscimol (0.2 µg/rat), selective GABA_BR agonist baclofen (0.5 µg/rat) or NMDAR antagonist D-AP5 (0.25 µg/rat) decreased step-through latency, indicating a memory retention impairment. Neither GABA_AR antagonist bicuculline (0.0625–0.25 µg/rat) nor GABA_BR antagonist phaclofen (0.1–0.5 µg/rat) altered memory retrieval by itself. Moreover, the lower dose of muscimol (0.05 µg/rat) decreased D-AP5 (0.125 µg/rat) response on memory acquisition, but bicuculline did not alter the D-AP5 response. Furthermore, baclofen and phaclofen at the dose of 0.1 µg/rat potentiated D-AP5 response at the doses of 0.0625 and 0.125 µg/rat, but abolished memory impairment induced by D-AP5 at the higher dose (0.25 µg/rat). The results suggest that the microinjection of GABA_A and GABA_B agents into the CA1 region differently affects memory acquisition deficit induced by D-AP5. The activation of GABA_ARs increased the impairment effect of D-AP5 on passive avoidance memory, but their blockade did not have an effect. Also, the activation or blockade of GABA_BRs induced a similar and dual effect.
The role of CA3 GABA<inf>B</inf> receptors on anxiolytic-like behaviors and avoidance memory deficit induced by D-AP5 with respect to Ca<sup>2 +</sup> ions
2017, Progress in Neuro-Psychopharmacology and Biological Psychiatry
Citation Excerpt :
Previous researchers have proved the involvement of the NMDA receptors (NMDARs) (Guimaraes et al., 1991) and GABA receptors (Millan, 2003), including GABAB receptors (GABABRs) (Helm et al., 2005; Sunyer et al., 2007) in the improvement of anxiety and memory states (Bowery et al., 2002, Joanna M Wierońska, 2011, Staubli et al., 1999). There are reports of the cognitive function enhancement in several species by GABABR antagonists in different functional tests (Mondadori et al., 1993) and it has been proposed that GABABR antagonism may enhance cognition by elevating the neural activity in the hippocampus (Cryan and Slattery, 2010). However, we still need a better understanding of the interaction between these two systems to be able to provide novel ways of treatment with fewer side effects.
Glutamatergic and GABAergic systems play key roles in the hippocampus and affect the pathogenesis of anxiety- and memory-related processes. Some investigations have assessed the role of balancing the function of these two systems in different areas of the central nervous system (CNS) as an approach to manage the related disorders. We investigated the anxiety and avoidance memory states using the test-retest protocol in the elevated plus maze to understand the role of GABA_B receptors (GABA_BRs) in relation to the NMDA receptor blockade by D-AP5 (an NMDA receptor antagonist). Also, we examined the function of Ca^2 + ions by blocking its entrance to the cell using SKF96365 (a Ca^2 + channel blocker). The drugs were injected into the CA3 region before the test. Our data showed that D-AP5 induced anxiolytic-like behaviors and impaired the avoidance memory. Injection of baclofen (a GABA_BR agonist), but not phaclofen (a GABA_BR antagonist) induced anxiolytic-like behaviors. Neither baclofen nor phaclofen altered avoidance memory-related behaviors. When baclofen was injected before D-AP5, it potentiated the anxiolytic-like behaviors induced by D-AP5, but counteracted its effect on avoidance memory. Phaclofen pretreatment attenuated D-AP5-induced anxiolytic-like behaviors, but potentiated its effect on avoidance memory. The effect of baclofen application before D-AP5 on anxiety and phaclofen application before D-AP5 on avoidance memory at the heist doses were accompanied by a decrease in locomotion. The application of SKF96365 did not alter anxiety-like behaviors but induced avoidance memory impairment. SKF96365 application before the combination of baclofen and D-AP5 counteracted the effects produced by the combination of baclofen and D-AP5 on anxiety and memory states. Our findings showed that the CA3 GABA_BRs had a critical role in anxiolytic-like behaviors and avoidance memory deficit induced by D-AP5 and confirmed the role of Ca^2 + ions in the observed results.
Possible involvement of the CA1 GABAergic system on harmaline induced memory consolidation deficit
2017, Brain Research Bulletin
Activation of the GABA_B receptors inhibit learning and memory processes. The current research was designed to examine the role of dorsal hippocampal (CA1) GABA_B receptors on harmaline induced memory consolidation deficit in mice. For this purpose, the effects induced by the GABA_B antagonist phaclofen and the GABA_B agonist baclofen on memory consolidation were assessed by using the step-down inhibitory avoidance task. Furthermore, the possible involvement of harmaline on GABA_B receptor’s effects was also assessed through using the same behavioral procedure. In a first dose response experiments, post-training intra-CA1 injections of phaclofen did not change while baclofen (0.1 μg/mouse) impaired animals’ performance in this task, suggesting a modulation of storage of information. Moreover, Post-training intra-peritoneal (i.p.) infusion of harmaline (2 and 5 mg/kg) also decreased memory consolidation. Interestingly, phaclofen at the sub-threshold dose (0.001 μg/mouse, intra-CA1), successfully antagonized the deficits on memory consolidation induced by the highest doses of harmaline (2 and 4 mg/kg, i.p.). On the other hand, non significant dose of baclofenc (0.001 μg/mouse, intra-CA1) potentiated impairment of memory consolidation induced by harmaline (2 mg/kg, i.p.). In addition in all experiments, locomotor activity did not alter significantly. These results indicate a) that the CA1 GABA_B receptors are involved in memory consolidation b) that harmaline interact with the CA1 GABA_B receptors in modulation of memory consolidation.
Role of GABA<inf>B</inf> receptors in learning and memory and neurological disorders
2016, Neuroscience and Biobehavioral Reviews
Citation Excerpt :
Given that baclofen can affect both acquisition and consolidation of this task, it would be expected that GABAB receptor antagonists also produce some effect. In the instances an antagonist is used to investigate task acquisition, a positive effect is found only in studies that administered an antagonist repeatedly and systemically prior to training (Getova and Dimitrova, 2007; Yu et al., 1997), or specifically when the drug is administered orally (Mondadori et al., 1993). When not administered systemically (Zarrindast et al., 2008) or only administered once (Dubrovina and Zinov'ev, 2008; Zarrindast et al., 1998), no effect is observed.
Although it is evident from the literature that altered GABA_B receptor function does affect behavior, these results often do not correspond well. These differences could be due to the task protocol, animal strain, ligand concentration, or timing of administration utilized. Because several clinical populations exhibit learning and memory deficits in addition to altered markers of GABA and the GABA_B receptor, it is important to determine whether altered GABA_B receptor function is capable of contributing to the deficits. The aim of this review is to examine the effect of altered GABA_B receptor function on synaptic plasticity as demonstrated by in vitro data, as well as the effects on performance in learning and memory tasks. Finally, data regarding altered GABA and GABA_B receptor markers within clinical populations will be reviewed. Together, the data agree that proper functioning of GABA_B receptors is crucial for numerous learning and memory tasks and that targeting this system via pharmaceuticals may benefit several clinical populations.

View all citing articles on Scopus

¹: The results were presented at the Second International GABA_B Meeting in Interlaken, Switzerland, October 21–23, 1992.

View full text

Regular articleCGP 36742: The first orally active GABAB blocker improves the cognitive performance of mice, rats, and rhesus monkeys

European Journal of Pharmacology

Brain Research

Trends in Pharmacological Science

Behavioural Brain Research

Behavioral and Neural Biology

European Journal of Pharmacology

The cholinergic hypothesis: A historical overview, current perspective, and future directions

GABAB antagonists: Potential new drugs

Pharmacology Communications

Biochemistry, electrophysiology and pharmacology of a new GABAB antagonist: CGP 35348

Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor

Nature

GABAergic modulation of memory

Post-training systemic and intraamygdala administration of the GABAB agonist Baclofen impairs retention

Behavioral and Neural Biology

GABAB autoreceptors regulate the induction of LTP

Nature

A physiological role for GABAB receptors in the central nervous system

Nature

Place memory and scene memory: Effects of fornix transsections in the monkey

Experimental Brain Research

A generalized Wilcoxon test for comparing arbitrarily single censored samples

Biometrika

Regular article
CGP 36742: The first orally active GABA_B blocker improves the cognitive performance of mice, rats, and rhesus monkeys

GABA_B antagonists: Potential new drugs

Biochemistry, electrophysiology and pharmacology of a new GABA_B antagonist: CGP 35348

Post-training systemic and intraamygdala administration of the GABA_B agonist Baclofen impairs retention

GABA_B autoreceptors regulate the induction of LTP

A physiological role for GABA_B receptors in the central nervous system